UNSPSC 51333409: Tolpiprazole

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8XP74P4HO3. European Medicines Agency schedules Tolpiprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11174MIG. Tolpiprazole generally arises in the molecular formula C17H24N4.

UNSPSC 51333409 Tolpiprazole is a Commodity code nominally describing a specific antiulcer pharmaceutical agent, but recent state and local solicitations show that this code tags a much broader set of pharmaceutical procurement activities—including naloxone, over-the-counter products, and generic multi-source medications supplied through established wholesaler networks and direct-to-manufacturer programs. State and local governments buying under this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, which extends to Oregon). The work spans both routine pharmaceutical supply contracts with fixed pricing and inventory management terms, and strategic market-research initiatives to explore alternative procurement models such as direct manufacturer relationships outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity appears concentrated in Florida, Texas, and the upper Midwest. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring electronic bid submission, E-Verify compliance, and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026 regarding direct-to-manufacturer prescription programs, seeking vendor capabilities for negotiated net-pricing models outside existing PBM and GPO arrangements—a preliminary market-intelligence phase before formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with pricing weighted 75 percent in evaluation and mandatory cGMP and Drug Supply Chain Security Act (DSCSA) certification. All three solicitations require vendor insurance, regulatory compliance, and supply-chain transparency, with no explicit set-aside designations identified in the available documentation.